Across TCGA pan-cancer cohorts, CYP4F8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP4F8 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CYP4F8 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CYP4F8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, PRAD, and SKCM are the cancer types where CYP4F8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.436	.011	28	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.967	0.828	.026	4	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →
STAD	OS	Median	II,III,IV	0.250	0.709	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CYP4F8 tumor-vs-normal RNA expression · all CYP4F8 data types